Adjunctive parenteral therapy with lipo-ecraprost, a prostaglandin E1 analog, in patients with critical limb ischemia undergoing distal revascularization does not improve 6-month outcomes

Journal of Vascular Surgery

Volumn 45, Issue 5, 2007, Pages 953-961

  Nehler, Mark R ^a   Brass, Eric P ^b   Anthony, Richard ^c   Dormandy, John ^d   Jiao, Jenny ^c   McNamara, Thomas O ^e   Hiatt, William R ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b HARBOR UCLA MEDICAL CENTER   (United States)

^c Catalyst Pharmaceutical Research   (United States)

^d ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^e David Geffen UCLA Medical Center   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ECRAPROST; LIPO ECRAPROST; PLACEBO; PROSTAGLANDIN E1 DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; AGED; ANKLE; ARTICLE; BYPASS SURGERY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DIARRHEA; DOUBLE BLIND PROCEDURE; ENDOVASCULAR SURGERY; FEMALE; FOLLOW UP; GRAFT PATENCY; HEADACHE; HEART INFARCTION; HEMODYNAMICS; HUMAN; HYPOTENSION; KNEE; LEG; LEG ARTERY; LEG REVASCULARIZATION; LIMB AMPUTATION; LIMB ISCHEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA AND VOMITING; PAIN; POPULATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STROKE; SURVIVAL; TACHYCARDIA; TREATMENT OUTCOME; VASODILATATION;

ADULT; AGED; AGED, 80 AND OVER; ALPROSTADIL; CHEMOTHERAPY, ADJUVANT; DOUBLE-BLIND METHOD; FEMALE; HUMANS; ISCHEMIA; LEG; MALE; MIDDLE AGED; PRODRUGS; TREATMENT OUTCOME; VASCULAR SURGICAL PROCEDURES;

EID: 34247337315     PISSN: 07415214     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jvs.2006.12.057     Document Type: Article

References (17)

1. Hiatt W.R. Medical treatment of peripheral arterial disease and claudication. N Engl J Med 344 (2001) 1608-1621
2. Dormandy J., Heeck L., and Vig S. Predicting which patients will develop chronic critical leg ischemia. Semin Vasc Surg 12 (1999) 138-141
3. Feinglass J., Pearce W.H., Martin G.J., Gibbs J., Cowper D., Sorensen M., et al. Postoperative and amputation-free survival outcomes after femorodistal bypass grafting surgery: findings from the Department of Veterans Affairs National Surgical Quality Improvement Program. J Vasc Surg 34 (2001) 283-290
4. Dormandy J., Heeck L., and Vig S. The fate of patients with critical leg ischemia. Semin Vasc Surg 12 (1999) 142-147
5. Adam D.J., Beard J.D., Cleveland T., Bell J., Bradbury A.W., Forbes J.F., et al. Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial. Lancet 366 (2005) 1925-1934
6. Goshima K.R., Mills Sr. J.L., and Hughes J.D. A new look at outcomes after infrainguinal bypass surgery: traditional reporting standards systematically underestimate the expenditure of effort required to attain limb salvage. J Vasc Surg 39 (2004) 330-335
7. Chung J., Bartelson B.B., Hiatt W.R., Peyton B.D., McLafferty R.B., Hopley C.W., et al. Wound healing and functional outcomes following infrainguinal bypass with reversed saphenous vein for critical limb ischemia. J Vasc Surg 43 (2006) 1183-1190
8. Brass E.P., Anthony R., Dormandy J., Hiatt W.R., Jiao J., Nakanishi A., et al. Intensive parenteral therapy with lipo-ecraprost, a lipid-based formulation of a prostaglandin E1 analog does not alter six-month outcomes in patients with critical leg ischemia who are not candidates for revascularization. J Vasc Surg 43 (2006) 752-759
9. Arosio E., Minuz P., Prior M., Zuliani V., Gaino S., De Marchi S., et al. Vascular adhesion molecule-1 and markers of platelet function before and after a treatment with iloprost or a supervised physical exercise program in patients with peripheral arterial disease. Life Sci 69 (2001) 421-433
10. Makino H., Aoki M., Hashiya N., Yamasaki K., Hiraoka K., Shimizu H., et al. Increase in peripheral blood flow by intravenous administration of prostaglandin E1 in patients with peripheral arterial disease, accompanied by up-regulation of hepatocyte growth factor. Hypertens Res 27 (2004) 85-91
11. Mehrabi M.R., Serbecic N., Tamaddon F., Pacher R., Horvath R., Mall G., et al. Clinical benefit of prostaglandin E1-treatment of patients with ischemic heart disease: stimulation of therapeutic angiogenesis in vital and infarcted myocardium. Biomed Pharmacother 57 (2003) 173-178
12. Salcedo R., Zhang X., Young H.A., Michael N., Wasserman K., Ma W.H., et al. Angiogenic effects of prostaglandin E2 are mediated by up-regulation of CXCR4 on human microvascular endothelial cells. Blood 102 (2003) 1966-1977
13. Igarashi R., Takenaga M., Takeuchi J., Kitagawa A., Matsumoto K., and Mizushima Y. Marked hypotensive and blood flow-increasing effects of a new lipo-PGE(1) (lipo-AS013) due to vascular wall targeting. J Control Release 71 (2001) 157-164
14. Gore S.M. Zelen randomisation. Lancet 2 (1984) 226-227
15. Rutherford R.B., Baker J.D., Ernst C., Johnston K.W., Porter J.M., Ahn S., et al. Recommended standards for reports dealing with lower extremity ischemia: revised version. J Vasc Surg 26 (1997) 517-538
16. Giswold M.E., Landry G.J., Taylor Jr. L.M., and Moneta G.L. Outcomes after redo procedures for failed mesenteric revascularization. Vasc Endovascular Surg 38 (2004) 315-319
17. Conte M.S., Bandyk D.S., Clowes A.W., Moneta G.L., Seely L., Lorenz T.J., et al., Prevent III investigators. Results of Prevent III: a multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery. J Vasc Surg 43 (2006) 742-751